• Losartan (ARB) in patients hospitalized for COVID-19 • Phase 2 RCT
• Losartan vs. placebo + standard care
•  N = 200
• Secondary outcome includes cardiovascular organ failure/dysfunction • Losartan 50 mg orally once daily (NCT04312009, 2020)